You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行》交銀國際:美臨牀腫瘤學會大會上多項國產創新藥重磅數據公佈 中國創新藥入選數量創新高
醫藥股H股今日(29日)向上,中生製藥(01177.HK)上揚5.5%報4.42元,石藥(01093.HK)公佈首季業績後股價彈高11.6%,康方生物(09926.HK)走高4%,而藥明康德(02359.HK)搶升6.6%,藥明生物(02269.HK)揚9.8%。 交銀國際發表報告表示,5月30日至6月3日,2025年美國臨牀腫瘤學會(ASCO)年會將在美國芝加哥正式召開。5月22日,ASCO 年會摘要全文公佈,其中包括恆瑞醫藥(01276.HK)、信達生物(01801.HK)、榮昌生物(09995.HK)、正大天晴、科倫博泰(06990.HK)在內的多家創新藥企展示了優異的臨牀數據。據統計,此次 ASCO 大會中國創新再創新高,中國藥企共有71 項原創性研究成果入選口頭髮言環節,其中11項研究將以重磅研究(Late Breaking Abstract, LBA)會議形式公佈。 據該行對部分國產創新藥梳理,達到重磅研究(LBA)的項目包括石藥及石藥旗下新諾威(300765.SZ)的「JMT101+伊立替康 +SG001 vs 瑞格非尼」(適應癌爲結直腸癌)、中生製藥有4項項目被列入LBA,包括「Benmelstobart+安羅替尼 vs K 藥」、「安羅替尼+化療 vs 貝伐 珠+化療」、「TQB2450±安羅替尼」及「STUPP 方案±安羅替尼」等。 交銀國際指2025年ASCO摘要中,中國創新藥入選數量再創新高,印證中國創新藥企研發競爭力實現跨越式突破,國際影響力日漸提高。ASCO大會召開在即(5月30日至6月3日),LBA重磅數據即將揭曉,創新藥板塊有望迎來關注熱潮、並有望在未來推動更多出海交易達成,市場情緒與板塊估值將進入正向修復通道。 考慮到板塊投資性價比顯着(估值仍顯着低於歷史平均值)、機構持倉處於低位、全鏈條支持創新藥相關利好政策持續落地,該行建議短期後續可重點關注:(1)榮昌生物、康方生物、信達生物、科倫博泰-B、德琪醫藥-B(06996.HK)等短期催化劑豐富、盈利高增長或盈虧平衡時間點明確、估值有較大彈性的創新藥股份;(2)先聲藥業(02096.HK)、翰森製藥(03692.HK)存在業績高增速+估值倍數擴張潛力的處方藥企;(3)隨着DRG/DIP改革影響基本消化完畢、醫保結算機制持續完善、鼓勵生育政策持續出臺,民營醫療 服務的盈利增長預期和估值有望逐步從底部回升,同時業務本身對地緣因素免疫,包括固生堂(02273.HK)、海吉亞醫療(06078.HK)、錦欣生殖(01951.HK)等。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account